In light of the ongoing tariff disputes initiated by the United States and retaliatory tariffs from other nations, Novo Nordisk, a prominent Danish healthcare company, has raised alarms about potential price hikes and product shortages. This concern resonates throughout the pharmaceutical industry, including players from India.
Lars Fruergaard Jørgensen, the President and CEO of Novo Nordisk, discussed how the company’s extensive global operations could help mitigate the adverse effects of tariffs, emphasizing its significant presence in the U.S. market. However, he also highlighted a broader industry concern regarding the potential for increased prices and shortages. This is largely because international pharmaceutical companies often source active pharmaceutical ingredients from lower-cost markets, complicating the movement of products across borders.
As the tariff conflict intensifies, with tariffs imposed by President Donald Trump on imports from Canada, Mexico, China, and others—including India—set to take effect on April 2, the pharmaceutical sector is bracing itself for the ramifications.
Novo Nordisk was recently in the spotlight after announcing a price reduction for its weight loss medication, Wegovy (semaglutide), in the U.S. They plan to deliver the drug directly to patients who pay out of pocket, without insurance.
The surge in popularity of semaglutide, marketed globally as Ozempic and Wegovy for diabetes management and weight loss, has led to significant demand and, consequently, supply shortages. Despite this, the company asserted that it would continue expanding the availability of the drug, even in regions with less stringent patent protections. While a specific timeline for the launch of the injectable form of the product in India was not provided, a representative from Novo Nordisk indicated that they are proceeding with the rollout, acknowledging that generic manufacturers are poised to introduce their own versions. An oral formulation of the medication is already accessible in India, with expectations that the patent could expire in some markets by 2026.
